Chlamydia Infection Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other), By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection), By End User (Hospitals, Specialty Clinics, Diagnostics Centre), By Region, and Competition Forecast

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 678.56 Million

CAGR (2023-2028)

6.06%

Fastest Growing Segment

Hospitals

Largest Market

North America


Market Overview

Global Chlamydia Infection Diagnostics Market stood at USD 678.56 Million in 2022 and is anticipated to grow at a CAGR of 6.06% through 2028. Chlamydia infection is one of the most prevalent sexually transmitted infections (STIs) worldwide, caused by the bacteria Chlamydia trachomatis. Left untreated, it can lead to serious health complications, including pelvic inflammatory disease, infertility, and increased susceptibility to other STIs. Timely and accurate diagnosis is crucial to prevent these adverse outcomes. The Chlamydia Infection Diagnostics Market has witnessed significant advancements in recent years, offering more effective and convenient diagnostic tools that empower healthcare providers and individuals to combat this silent epidemic. Chlamydia is a silent infection, often presenting with no noticeable symptoms. This characteristic, coupled with the stigma surrounding STIs, leads to underdiagnosis and undertreatment. According to the World Health Organization (WHO), an estimated 131 million new cases of chlamydia occurred globally in 2020, making it one of the most commonly reported bacterial STIs. The burden is particularly high among sexually active young individuals, with the age group of 15 to 24 being the most affected. Traditionally, the gold standard for diagnosing chlamydia infections has been nucleic acid amplification tests (NAATs), such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA). These tests amplify and detect the genetic material of the bacteria, offering high sensitivity and specificity. However, these methods often require specialized laboratories and trained personnel, making them less accessible and delaying results.

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

In recent years, the global healthcare landscape has witnessed a significant increase in the prevalence of Chlamydia infections, propelling the growth of the Chlamydia infection diagnostics market. Chlamydia is one of the most common sexually transmitted infections (STIs) globally, affecting millions of individuals each year. The rising incidence of this infection has brought to light the critical need for accurate and timely diagnostics, leading to the expansion of the diagnostics market focused on Chlamydia infections. Chlamydia trachomatis, the bacterium responsible for causing Chlamydia infections, primarily affects the genital tract but can also manifest in the eyes and respiratory system. The infection is often asymptomatic, which makes its early detection and diagnosis challenging. If left untreated, Chlamydia infections can result in severe complications, such as pelvic inflammatory disease (PID) in women, leading to infertility, ectopic pregnancy, and chronic pain. In men, untreated Chlamydia infections can lead to epididymitis, which can cause testicular pain and, in rare cases, infertility. The driving force behind the growth of the Chlamydia infection diagnostics market is the alarming increase in the prevalence of Chlamydia infections across all age groups. Young adults and adolescents are particularly susceptible due to their higher likelihood of engaging in risky sexual behaviors and their limited awareness of the importance of safe sex practices and regular screening. Additionally, changing cultural attitudes toward sex and relationships, as well as the stigma associated with discussing and testing for STIs, further contribute to the underdiagnosis and underreporting of Chlamydia infections. To combat the rising prevalence of Chlamydia infections, healthcare systems and organizations are emphasizing the importance of regular screening, especially for sexually active individuals and those with multiple partners. This emphasis on early detection and treatment has sparked a surge in demand for reliable and accurate Chlamydia infection diagnostics. Consequently, the market has witnessed the development of innovative diagnostic technologies and tools to enable efficient and convenient testing.

Increasing Focus on Women's Health is Driving Chlamydia Infection Diagnostics Market

In The emphasis on women's health has grown significantly in recent years. A more comprehensive understanding of the unique health needs and challenges faced by women has driven this shift. Medical research and advocacy efforts have shed light on the disparities in healthcare outcomes between genders, urging healthcare systems to prioritize women's health concerns. As a result, there is a greater awareness of the importance of early detection and management of Chlamydia infections to prevent long-term health complications in women. Public health campaigns and education initiatives have raised awareness about Chlamydia infections and their potential consequences, encouraging individuals to seek testing and treatment. Advances in diagnostic technologies have led to more accurate and accessible methods for detecting Chlamydia infections. These methods are essential for early detection and effective management. Routine screenings for Chlamydia have become a crucial component of preventive care, especially for sexually active women. Healthcare providers are now more proactive in recommending regular screenings. Government policies and guidelines have increasingly stressed the importance of STI testing, particularly among vulnerable populations such as young women and pregnant women. Ongoing research in the field of Chlamydia infections has resulted in improved understanding of the disease, leading to the development of new diagnostic tools and treatment options.


Download Free Sample Report

Key Market Challenges

Underdiagnosis and Lack of Awareness

Despite its prevalence, chlamydia infection often goes undiagnosed due to asymptomatic cases and limited awareness. Many individuals, especially young adults, may not exhibit symptoms, leading to a failure to seek testing. Additionally, the lack of comprehensive sex education and stigma surrounding STIs contribute to a lower demand for diagnostics. These factors collectively hinder efforts to accurately estimate the true burden of chlamydia infection and undermine public health interventions.

Need for Enhanced Screening Programs

Current chlamydia screening programs are typically targeted at high-risk populations, such as sexually active young adults. While these efforts are valuable, they may not capture all cases, particularly among less-obvious risk groups. Expanding and optimizing screening programs to reach a wider demographic is essential to identify and treat infections promptly.

Sample Collection and Testing Challenges

Accurate diagnosis of chlamydia infection relies on reliable sample collection and testing methods. Traditional methods involve invasive procedures, which may deter individuals from getting tested. Newer non-invasive methods, like urine-based tests, have emerged, but they still require proper handling and laboratory facilities. Ensuring convenient, accessible, and accurate sample collection and testing is a persistent challenge.

Key Market Trends

Technological Advancements

One of the most significant developments in Chlamydia infection diagnostics is the advent of nucleic acid amplification techniques (NAATs). These methods involve the amplification of Chlamydia-specific nucleic acids (DNA or RNA) to detect the presence of the bacterium even at low concentrations. NAATs, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), and loop-mediated isothermal amplification (LAMP), offer high sensitivity and specificity, enabling early and accurate detection of Chlamydia infections. These techniques have revolutionized diagnostic accuracy, reducing false negatives and improving patient outcomes. In recent years, the ubiquity of smartphones has been harnessed to advance Chlamydia infection diagnostics. Researchers have developed smartphone-based diagnostic platforms that use the phone's camera and processing capabilities to analyze test results. Users can capture images of diagnostic test strips or devices, and specialized software interprets the results. This approach not only enhances accessibility but also reduces the need for specialized equipment and training. Smartphone-based diagnostics have the potential to empower individuals to monitor their health in the comfort of their own homes. While nucleic acid-based diagnostics are highly sensitive, they primarily detect active infections. Serological and antibody-based assays focus on identifying the body's immune response to Chlamydia infection. These assays measure the presence of antibodies produced in response to the infection, providing insights into both current and past infections. Serological tests are particularly useful for epidemiological studies and identifying individuals with a history of Chlamydia exposure. Combining nucleic acid-based and serological approaches offers a comprehensive picture of an individual's infection history and status.

Segmental Insights

Test Type Insights

In 2022, the Chlamydia Infection Diagnostics market was dominated by the Nucleic Acid Amplification Test (NAAT) segment and is predicted to continue expanding over the coming years. Nucleic Acid Amplification Test (NAAT) is a powerful molecular technique designed to amplify and detect specific sequences of DNA or RNA within a biological sample. The primary purpose of NAAT is to identify the presence of pathogens, such as bacteria, viruses, and fungi, by amplifying their genetic material to levels detectable by modern laboratory equipment. This method is incredibly sensitive, enabling the detection of even a few copies of the target nucleic acid sequence.

 

Type of Infections Insights

In 2022, the Chlamydia Infection Diagnostics market was dominated by the Genital chlamydia infection segment and is predicted to continue expanding over the coming years. Genital chlamydia infection, caused by the bacterium Chlamydia trachomatis, is one of the most common sexually transmitted infections (STIs) worldwide. This infection can affect both men and women, often showing mild or no symptoms initially, but if left untreated, it can lead to serious health complications. Education about the causes, symptoms, testing, treatment, and prevention of genital chlamydia is crucial to controlling its spread and minimizing its impact on public health. 


Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Chlamydia Infection Diagnostics Market North America's dominance in Chlamydia infection diagnostics is partly attributed to the region's cutting-edge technological advancements. Polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) have revolutionized diagnostic accuracy. These techniques amplify the genetic material of the bacteria, allowing even small traces of the infection to be detected. North American laboratories and research institutions have led the way in refining these diagnostic methods, increasing their sensitivity, specificity, and speed. The region's advanced healthcare infrastructure also plays a pivotal role in Chlamydia infection diagnostics. North America boasts a well-developed healthcare system with widespread access to medical facilities, testing centers, and professional healthcare providers. This accessibility enables individuals to seek medical attention and get tested promptly. Moreover, public health initiatives and educational campaigns raise awareness about the importance of regular testing, further contributing to early detection and diagnosis.

Recent Developments

  • In May 2022, Becton, Dickinson and Company introduced the BD COR MX device in the United States, which is an automated molecular diagnostics platform capable of high-throughput testing. This platform includes the BD CTGCTV2 test, designed to identify Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis infections. This advancement effectively tackles common non-viral sexually transmitted infections by providing both convenience and precise results.
  • In August 2023, The USA is set to introduce a previously used antibiotic as a preventive pill in its ongoing efforts to enhance its fight against sexually transmitted infections (STIs).The utilization of DoxyPEP, also known as doxycycline, subsequent to unprotected sexual activity, has demonstrated a noteworthy reduction in the likelihood of contracting chlamydia, gonorrhea, and syphilis.

Key Market Players

  • Abbott
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc
  • Quidel Corporation
  • DiaSorin SpA
  • AstraZeneca
  • Teva Pharmaceutical Industries Limited

 By Test Type

By Type of Infections

By End User

By Region

•       Polypropylene

•       Culture Test

•       Nucleic Acid Amplification Test (NAAT)

•       Direct Fluorescent Antibody Test

•       Serology Test

•       Other

•       Genital Chlamydia Infection

•       Rectal Chlamydia Infection

•       Ocular Chlamydia Infection

•       Hospitals

•       Specialty Clinics

•       Diagnostics Centre

•       North America

•       Asia-Pacific

•       Europe

•       Middle East & Africa

•       South America

 

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

            ·         Chlamydia Infection Diagnostics Market, By Test Type:

o   Culture Test

o   Nucleic Acid Amplification Test (NAAT)

o   Direct Fluorescent Antibody Test

o   Serology Test

o   Other

            ·         Chlamydia Infection Diagnostics Market, By Type of Infections:

o   Genital Chlamydia Infection

o   Rectal Chlamydia Infection

o   Ocular Chlamydia Infection

            ·         Chlamydia Infection Diagnostics Market, By End User:

o   Hospitals

o   Specialty Clinics

o   Diagnostics Centre

            ·         Chlamydia Infection Diagnostics Market, By Region:

o   North America

o   Asia-Pacific

o   Europe

o   Middle East & Africa

o   South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Chlamydia Infection Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validations

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Chlamydia Infection Diagnostics Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)

5.2.2.     By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)

5.2.3.     By End User (Hospitals, Specialty Clinics, Diagnostics Centre)

5.2.4.     By Region

5.2.5.     By Company (Shares of Top 5 Market Players)

5.3.  Market Map

5.3.1.     By Test Type

5.3.2.     By Type of Infections

5.3.3.     By End User

5.3.4.     By Region

6.    North America Chlamydia Infection Diagnostics Market Outlook

6.1.  Market Size & Forecast          

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Test Type

6.2.2.     By Type of Infections

6.2.3.     By End User

6.2.4.     By Country

6.2.4.1.         United States Chlamydia Infection Diagnostics Market Outlook

6.2.4.1.1.             Market Size & Forecast

6.2.4.1.1.1. By Value

6.2.4.1.2.             Market Share & Forecast

6.2.4.1.2.1. By Test Type

6.2.4.1.2.2. By Type of Infections

6.2.4.1.2.3. By End User 

6.2.4.2.         Canada Chlamydia Infection Diagnostics Market Outlook

6.2.4.2.1.             Market Size & Forecast

6.2.4.2.1.1. By Value

6.2.4.2.2.             Market Share & Forecast

6.2.4.2.2.1. By Test Type

6.2.4.2.2.2. By Type of Infections

6.2.4.2.2.3. By End User

6.2.4.3.         Mexico Chlamydia Infection Diagnostics Market Outlook

6.2.4.3.1.             Market Size & Forecast

6.2.4.3.1.1. By Value

6.2.4.3.2.             Market Share & Forecast

6.2.4.3.2.1. By Test

6.2.4.3.2.2. By Type of Infections

6.2.4.3.2.3. By End User

7.    Europe Chlamydia Infection Diagnostics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Test Type

7.2.2.     By Type of Infections

7.2.3.     By End User

7.2.4.     By Country

7.2.4.1.         France Chlamydia Infection Diagnostics Market Outlook

7.2.4.1.1.             Market Size & Forecast

7.2.4.1.1.1. By Value

7.2.4.1.2.             Market Share & Forecast

7.2.4.1.2.1. By Test Type

7.2.4.1.2.2. By Type of Infections

7.2.4.1.2.3. By End User

7.2.4.2.         Germany Chlamydia Infection Diagnostics Market Outlook

7.2.4.2.1.             Market Size & Forecast

7.2.4.2.1.1. By Value

7.2.4.2.2.             Market Share & Forecast

7.2.4.2.2.1. By Test Type

7.2.4.2.2.2. By Type of Infections

7.2.4.2.2.3. By End User

7.2.4.3.         United Kingdom Chlamydia Infection Diagnostics Market Outlook

7.2.4.3.1.             Market Size & Forecast

7.2.4.3.1.1. By Value

7.2.4.3.2.             Market Share & Forecast

7.2.4.3.2.1. By Test Type

7.2.4.3.2.2. By Type of Infections

7.2.4.3.2.3. By End User

7.2.4.4.         Italy Chlamydia Infection Diagnostics Market Outlook

7.2.4.4.1.             Market Size & Forecast

7.2.4.4.1.1. By Value

7.2.4.4.2.             Market Share & Forecast

7.2.4.4.2.1. By Test Type

7.2.4.4.2.2. By Type of Infections

7.2.4.4.2.3. By End User

7.2.4.5.         Spain Chlamydia Infection Diagnostics Market Outlook

7.2.4.5.1.             Market Size & Forecast

7.2.4.5.1.1. By Value

7.2.4.5.2.             Market Share & Forecast

7.2.4.5.2.1. By Test Type

7.2.4.5.2.2. By Type of Infections

7.2.4.5.2.3. By End User

8.    Asia Pacific Chlamydia Infection Diagnostics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Test Type

8.2.2.     By Type of Infections

8.2.3.     By End User

8.2.4.     By Country

8.2.4.1.         China Chlamydia Infection Diagnostics Market Outlook

8.2.4.1.1.             Market Size & Forecast

8.2.4.1.1.1. By Value

8.2.4.1.2.             Market Share & Forecast

8.2.4.1.2.1. By Test Type

8.2.4.1.2.2. By Type of Infections

8.2.4.1.2.3. By End User

8.2.4.2.         India Chlamydia Infection Diagnostics Market Outlook

8.2.4.2.1.             Market Size & Forecast

8.2.4.2.1.1. By Value

8.2.4.2.2.             Market Share & Forecast

8.2.4.2.2.1. By Test Type

8.2.4.2.2.2. By Type of Infections

8.2.4.2.2.3. By End User

8.2.4.3.         South Korea Chlamydia Infection Diagnostics Market Outlook

8.2.4.3.1.             Market Size & Forecast

8.2.4.3.1.1. By Value

8.2.4.3.2.             Market Share & Forecast

8.2.4.3.2.1. By Test Type

8.2.4.3.2.2. By Type of Infections

8.2.4.3.2.3. By End User

8.2.4.4.         Japan Chlamydia Infection Diagnostics Market Outlook

8.2.4.4.1.             Market Size & Forecast

8.2.4.4.1.1. By Value

8.2.4.4.2.             Market Share & Forecast

8.2.4.4.2.1. By Test Type

8.2.4.4.2.2. By Type of Infections

8.2.4.4.2.3. By End User

8.2.4.5.         Australia Chlamydia Infection Diagnostics Market Outlook

8.2.4.5.1.             Market Size & Forecast

8.2.4.5.1.1. By Value

8.2.4.5.2.             Market Share & Forecast

8.2.4.5.2.1. By Test Type

8.2.4.5.2.2. By Type of Infections

8.2.4.5.2.3. By End User

9.    South America Chlamydia Infection Diagnostics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Type of Infections

9.2.3.     By End User

9.2.4.     By Country

9.2.4.1.         Brazil Chlamydia Infection Diagnostics Market Outlook

9.2.4.1.1.             Market Size & Forecast

9.2.4.1.1.1. By Value

9.2.4.1.2.             Market Share & Forecast

9.2.4.1.2.1. By Test Type

9.2.4.1.2.2. By Type of Infections

9.2.4.1.2.3. By End User

9.2.4.2.         Argentina Chlamydia Infection Diagnostics Market Outlook

9.2.4.2.1.             Market Size & Forecast

9.2.4.2.1.1. By Value

9.2.4.2.2.             Market Share & Forecast

9.2.4.2.2.1. By Test Type

9.2.4.2.2.2. By Type of Infections

9.2.4.2.2.3. By End User

9.2.4.3.         Colombia Chlamydia Infection Diagnostics Market Outlook

9.2.4.3.1.             Market Size & Forecast

9.2.4.3.1.1. By Value

9.2.4.3.2.             Market Share & Forecast

9.2.4.3.2.1. By Test Type

9.2.4.3.2.2. By Type of Infections

9.2.4.3.2.3. By End User

10.  Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.2.  By Type of Infections

10.2.3.  By End User

10.2.4.  By Country

10.2.4.1.      South Africa Chlamydia Infection Diagnostics Market Outlook

10.2.4.1.1.           Market Size & Forecast

10.2.4.1.1.1.               By Value

10.2.4.1.2.           Market Share & Forecast

10.2.4.1.2.1.               By Test Type

10.2.4.1.2.2.               By Type of Infections

10.2.4.1.2.3.               By End User

10.2.4.2.      Saudi Arabia Chlamydia Infection Diagnostics Market Outlook

10.2.4.2.1.           Market Size & Forecast

10.2.4.2.1.1.               By Value

10.2.4.2.2.           Market Share & Forecast

10.2.4.2.2.1.               By Test Type

10.2.4.2.2.2.               By Type of Infections

10.2.4.2.2.3.               By End User

10.2.4.3.      UAE Chlamydia Infection Diagnostics Market Outlook

10.2.4.3.1.           Market Size & Forecast

10.2.4.3.1.1.               By Value

10.2.4.3.2.           Market Share & Forecast

10.2.4.3.2.1.               By Test Type

10.2.4.3.2.2.               By Type of Infections

10.2.4.3.2.3.               By End User

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Market Trends & Developments

12.1.              Recent Development

12.2.              Mergers & Acquisitions

12.3.              Product Launches

13.  Competitive Landscape

13.1.              Abbott Laboratories, Inc.

13.2.              Becton, Dickinson and Company

13.3.              Bio-Rad Laboratories, Inc

13.4.              Quidel Corporation

13.5.              DiaSorin SpA

13.6.              AstraZeneca

13.7.              Teva Pharmaceutical Industries Limited

14.  Strategic Recommendations

15. About us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Chlamydia Infection Diagnostics Market was estimated to be USD 678.56 Million in 2022.

down-arrow

Abbott, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc, Quidel Corporation, DiaSorin SpA, AstraZeneca, Teva Pharmaceutical Industries Limited are some of the key players operating in the Global Chlamydia Infection Diagnostics Market.

down-arrow

North America has dominated the growth of Global Chlamydia Infection Diagnostics Market in the forecast period. The high prevalence of Chlamydia Infection in North America has contributed to the region's dominance in the market. The economic stability of North American countries has enabled them to invest in large-scale healthcare projects, further driving the demand for Chlamydia Infection Diagnostics.

down-arrow

Rising Prevalence of Chlamydia Infections and increasing awareness regarding women’s health are the major drivers for the Global Chlamydia Infection Diagnostics Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Chlamydia Infection Diagnostics Market to be Dominated by Nucleic Acid Amplification Test (NAAT) Through 2028

Nov, 2023

Rising Prevalence of Chlamydia Infections and increasing awareness regarding women’s health are driving Global Chlamydia Infection Diagnostics Market in the forecast period 2024-2028.

Why Choose Us